Tumor-specific CD8+ and CD4+ T cells infiltrate the tumor site after the recognition of tumor-specific or tumor-associated antigens through HLA class I and class II molecules, respectively, which facilitate the immune mechanisms in synergy with B cells. This evidence concerns the gene CD4 and neoplasm.